Form 4: Harmony Biosciences Director Gary Sender Acquires Stock Options
SEC Form 4 Filing
Director Gary Sender acquired 14,522 stock options in Harmony Biosciences Holdings, Inc. on May 15, 2025.
Summary
- On May 15, 2025, Gary Sender, a director of Harmony Biosciences Holdings, Inc., acquired 14,522 stock options.
- The options have an exercise price of $34.23.
- The options vest on the earlier of May 15, 2026, or the date of the next annual meeting following the grant date, contingent upon continued service.
- The expiration date for these options is May 15, 2035.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard regulatory filing about stock option grants. It doesn't inherently indicate positive or negative sentiment.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of transaction: Gary Sender acquired stock options. |
| 05/15/2026 | Earliest vesting date for the stock options. |
| 05/16/2025 | Date of signature for the Form 4 filing. |
| 05/15/2035 | Expiration date of the stock options. |
Keywords
stock options, Form 4, director, HRMY, Harmony Biosciences, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.